FoundationOne®Heme

What is FoundationOne Heme?

FoundationOne Heme

FoundationOne Heme is a comprehensive genomic profiling (CGP) test combining DNA and RNA sequencing for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. FoundationOne Heme detects known, novel, and complex fusion events as well as other common genomic alterations (substitutions, indels, and CNVs). This laboratory developed test (LDT) can be used by physicians to identify potential targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses.

Cancer Type

  • Hematologic Malignancies,
  • Sarcomas,
  • Solid Tumors

Turnaround Time

2 weeks from receipt of specimen

Sample Type

  • FFPE Tissue,
  • Peripheral Whole Blood,
  • Bone Marrow Aspirate
Image
F1H_01_Heme_image01-01 (1).png

>400 DNA-sequenced genes and >250 RNA-sequenced genes

Combines DNA and RNA sequencing to detect all four main classes of genomic alterations, including sensitive identification of translocations and fusions

Image
F1H_02_Heme_image02-01 (1).png

Valuable insights to help guide treatment strategies

Expansive gene panel provides broad coverage across guideline-recommended genes in leukemias and MDS.¹⁻³

Image
F1H_03_Heme_image03-01 (1).png

Multiple sample types accepted

FoundationOne Heme is validated for FFPE tissue, peripheral whole blood, bone marrow aspirate, and extracted nucleic acid

Real-life Results

Real-life Results

Learn more about the clinical utility of FoundationOne Heme in a number of cancer types.

Sample report

FoundationOne Heme Acute Myeloid Leukemia (AML) Sample Report

View a FoundationOne Heme AML sample report. This report shows results with an IDH2 and TET2 alteration detected.

 

Download sample report

Blog post

Can Rapid Precision Medicine Help Older Adults With AML?

The findings from the Beat AML Master trial offer new insights that, we believe, can help change clinical practice because they validate a framework for rapid precision medicine that improves outcome. Because blood cancers are so complex, they require a sophisticated strategy to understand each patient’s unique cancer as well as the treatments that have the best chance at improving survival.

Read full blog post
 

We Have Even More to Offer

Learn more about our other tests: FoundationOne®CDx and FoundationOne®Liquid CDx. You can also explore our decision support, report integration, and clinical research and trial matching services.

Need More Details?

Our client services team is here to help, Monday through Friday 8AM – 8PM EST.

Contact Us

Additional Notes

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

1Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021.  All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

2Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2021. © National Comprehensive Cancer Network, Inc. 2021.  All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

3Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2021. © National Comprehensive Cancer Network, Inc. 2021.  All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

4Casali, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology. 2018;29(Supp 4):iv51-iv67. doi:10.1093/annonc/mdy096.

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine.  It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on our laboratory developed test (LDT) please see the Technical Specifications at www.foundationmedicine.com